Clinical trials: Ribavirin
- Drug or intervention Ribavirin
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Hepatitis C
The Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C Patients
This is an open label, dose ranging, phase1a/1b clinical trial to study the safety, Pharmacokinetics and Pharmacodynamics of Peglamda 60, 120, 180 and 240 mcg in healthy volunteers and antiviral activity of once weekly Peglamda…
- Trial name
- NCT02063607
- Testing
- Peginterferon lambda
- Where
- Vietnam
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Nanogen Pharmaceutical Biotechnology Joint Stock Company
Hepatitis C Infection
Study of a New MVA Vaccine for Hepatitis C Virus
The study is aimed at assessing the safety of AdCh3NSmut and the new candidate vaccine MVA-NSmut when administered sequentially, or alone, to healthy volunteers and patients with hepatitis C virus infection The study also aims at…
- Trial name
- NCT01296451
- Testing
- MVA-NSmut, AdCh3NSmut, AdCh3NSmut1
- Where
- 3 sites in United Kingdom
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- ReiThera Srl
Hepatic Insufficiency
Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment
The primary objectives were: To determine the effects of steady state TPV co-administered with low dose RTV on steady state PegIFN and RBV in HIV negative subjects with mild hepatic impairment (scheme A) To determine the effects…
- Trial name
- NCT02259855
- Testing
- Tipranavir, Ritonavir, Pegylated interferon
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Safety, Tolerability, and Pharmacokinetics of Inhaled Virazole Administered Via Air-Jet Nebulizer in Healthy Volunteers
This study is a Phase 1a, randomized, double-blind, placebo-controlled, safety, tolerability, and PK study in healthy adult volunteers. Participants were screened for eligibility within 14 days prior to enrollment.
- Trial name
- NCT05229510
- Testing
- 50 mg/mL Virazole Inhalant Product, 100 mg/mL Virazole Inhalant Product
- Where
- Canada
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Chronic Hepatitis C
Relative Bioavailability Study of Ribavirin 200 Capsules and Rebetol 200 mg Capsules in Females Under Non-Fasting Conditions
The purpose of this study is to demonstrate the relative bioavailability of Ribavirin 200 capsules and Rebetol 200 mg capsules in females under non-fasting conditions.
- Trial name
- NCT00959933
- Testing
- Ribavirin 200 Capsules (Geneva Pharmaceutical, U.S.A.), Rebetol 200 Capsules (Schering Corporation, U.S.A.)
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Sandoz
Healthy Volunteer
A Bioequivalence Study of an Oral Solution of Copegus (Ribavirin) Compared to Copegus Tablets
This four-period, single-center, open-label, single-dose, randomized, cross-over study will assess the bioequivalence and safety of an oral solution of Copegus (ribavirin) compared to a Copegus tablet in healthy adult volunteers.
- Trial name
- NCT01697436
- Testing
- ribavirin [Copegus]
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Healthy
Ribavirin 200 mg Tablets Under Non-Fasting Conditions
The objective of this study is to compare the relative bioavailability of ribavirin 200 mg tablets (manufactured by TEVA Pharmaceutical Industries, Ltd.
- Trial name
- NCT00835536
- Testing
- Ribavirin 200 mg tablets, COPEGUS™ 200 mg Tablets
- Where
- 2 sites in United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Healthy Volunteer
A Study to Compare the Bioavailability of Copegus and Vilona® in Healthy Volunteers
This prospective, randomized, single-blind, cross-over study will compare the bioavailability of Copegus (ribavirin) administered as tablets and ribavirin administered as capsules in healthy volunteers.
- Trial name
- NCT01615393
- Testing
- ribavirin [Copegus], ribavirin [Vilona]
- Where
- Mexico
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis C
Relative Bioavailability Study of Ribavirin 200 Capsules and Rebetol 200 mg Capsules in Females Under Fasting Conditions
The purpose of this study is to demonstrate the relative bioavailability of Ribavirin 200 capsules and Rebetol 200 mg capsules in females under fasting conditions.
- Trial name
- NCT00960479
- Testing
- Ribavirin 200 mg Oral Capsule (Geneva Pharmaceutical, U.S.A.), Rebetol 200 mg Oral Capsule (Schering Corporation, U.S.A.)
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Sandoz
Healthy
Ribavirin 200 mg Tablets Under Fasting Conditions
The objective of this study is to compare the relative bioavailability of ribavirin 200 mg tablets (manufactured by TEVA Pharmaceutical Industries, Ltd.
- Trial name
- NCT00835146
- Testing
- Ribavirin 200 mg tablets, COPEGUS™
- Where
- 2 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA